Lenvatinib mesylate is under clinical development by Eisai and currently in Phase I for Epithelial Ovarian Cancer.

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III drugs for Gastric Cancer have a 46% phase transition ...

A 14-year-old Asian young woman presented for a routine school physical examination with a 4-month history of an enlarging, nontender mass overlying her left scapula. She initially believed that ...